In 2016 the world was given a set of new development goals to aspire to – from the eight Millennium Development Goals (MDGs) set in 2000 we are now working to achieve the 17 goals outlined by the UN’s Agenda 2030 for Sustainable Development (the SDGs).
MMV, as a leading member of the malaria community, is committed to reducing the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs. It is aligned to the SDGs, working to stop malaria epidemics and to reduce this unacceptable loss of life to zero.
The transformative approach of the SDGs weaves together the numerous strands of sustainable development into an integrated whole. Each of the 17 goals impacts the other. Achieving Goal 3b, which targets an end to malaria epidemics by 2030, will have enormous impact on the goals to end poverty (Goal 1), ensure newborns have a healthier start in life (Goal 3), create a more productive workforce (Goal 8), make sure children go to school and learn more effectively (Goal 4); and will make use of multi-sectoral partnerships to eliminate malaria (Goal 17).1
These are all extremely ambitious goals. The challenges ahead are real and the resources required significant, but the prize – a world free of malaria – is more than worth the effort.
For more information about the Sustainable Development Goals, go to the sustainable development knowledge platform.